{"id":6751,"date":"2025-06-12T12:58:36","date_gmt":"2025-06-12T16:58:36","guid":{"rendered":"https:\/\/neuro.bluehat.hosting\/recherche\/myasthenia-gravis\/"},"modified":"2025-11-04T08:20:55","modified_gmt":"2025-11-04T13:20:55","slug":"myasthenie-grave","status":"publish","type":"page","link":"https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/myasthenie-grave\/","title":{"rendered":"Myasth\u00e9nie grave"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"6751\" class=\"elementor elementor-6751 elementor-2643\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ddb8331 e-con-full animated-slow e-flex e-con e-parent\" data-id=\"ddb8331\" data-element_type=\"container\" id=\"blur-image\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;,&quot;animation&quot;:&quot;none&quot;,&quot;animation_delay&quot;:0}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-9db3503 elementor-widget__width-initial elementor-widget elementor-widget-heading\" data-id=\"9db3503\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Myasth\u00e9nie grave\n<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4a95441 elementor-widget__width-initial elementor-widget elementor-widget-heading\" data-id=\"4a95441\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">La derni\u00e8re d\u00e9cennie a profond\u00e9ment transform\u00e9 le paysage th\u00e9rapeutique de la myasth\u00e9nie grave. De nouveaux traitements aux m\u00e9canismes innovants, notamment la d\u00e9pl\u00e9tion des lymphocytes B, l\u2019inhibition du compl\u00e9ment et le blocage du r\u00e9cepteur Fc n\u00e9onatal, sont d\u00e9sormais disponibles et offrent la perspective de r\u00e9missions prolong\u00e9es.\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-19e9c5b elementor-align-left elementor-widget elementor-widget-button\" data-id=\"19e9c5b\" data-element_type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"\/myasthenia-gravis\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Participer<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-3d6eecc e-con-full e-flex e-con e-parent\" data-id=\"3d6eecc\" data-element_type=\"container\" id=\"horizontal-scroll\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t<div class=\"elementor-element elementor-element-08f2df5 e-con-full e-flex e-con e-child\" data-id=\"08f2df5\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-97503f4 elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile elementor-widget elementor-widget-heading\" data-id=\"97503f4\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Active and Recruiting<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c96c18a elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile elementor-widget elementor-widget-heading\" data-id=\"c96c18a\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h4 class=\"elementor-heading-title elementor-size-default\">CA-NEU-96 Vivgard in IVIG (argenx)<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-954f9b9 elementor-widget elementor-widget-text-editor\" data-id=\"954f9b9\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>La myasth\u00e9nie grave (MG) est un trouble auto-immun chronique qui touche la jonction neuromusculaire, c\u2019est-\u00e0-dire la connexion entre les nerfs et les muscles. Dans la MG, le syst\u00e8me immunitaire produit par erreur des anticorps qui perturbent la communication neuromusculaire, entra\u00eenant une faiblesse et une fatigabilit\u00e9 musculaires.<\/p>\n<p>Cette affection peut \u00eatre class\u00e9e selon les anticorps pr\u00e9sents. Certains patients sont positifs pour les anticorps AChR, MuSK ou LRP4, tandis que d\u2019autres sont s\u00e9ron\u00e9gatifs, c\u2019est-\u00e0-dire qu\u2019aucun anticorps sp\u00e9cifique n\u2019est d\u00e9tect\u00e9. Cliniquement, on distingue deux formes principales : la forme oculaire, limit\u00e9e aux muscles des yeux, et la forme g\u00e9n\u00e9ralis\u00e9e, qui touche plusieurs groupes musculaires dans l\u2019ensemble du corps.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-f4ef2f3 e-con-full e-flex e-con e-child\" data-id=\"f4ef2f3\" data-element_type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-21fc1c5 elementor-widget elementor-widget-html\" data-id=\"21fc1c5\" data-element_type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\n\/\/ Scroll to top on page load\nwindow.onload = function() {\n    window.scrollTo(0, 0);\n};\n\n\/\/ Alternative that works with turbolinks (if you're using that)\ndocument.addEventListener('DOMContentLoaded', function() {\n    window.scrollTo(0, 0);\n});\n<\/script>\n<script>\ndocument.addEventListener('DOMContentLoaded', function () {\n    const scrollContainer = document.querySelector('#horizontal-scroll');\n\n    \/\/ Add a check to ensure the element exists before trying to manipulate it\n    if (!scrollContainer) {\n        console.warn('Element #horizontal-scroll not found. Script will not run.');\n        return;\n    }\n\n    let lastScrollTop = 0;\n    let isScrollingDown = false;\n\n    \/\/ Define key scroll points\n    const activationScrollPoint = 300; \/\/ When the container starts to appear\n    const fullRevealScrollPoint = 800; \/\/ When the container is fully visible (right: 0%)\n    const stickToTopScrollPoint = 900; \/\/ When the container transitions from fixed to sticky\/absolute at the top\n\n    \/\/ Initial state setup\n    scrollContainer.style.opacity = '0';\n    scrollContainer.style.right = '-100%'; \/\/ Start fully off-screen to the right\n    scrollContainer.style.position = 'fixed';\n    scrollContainer.style.top = '0px'; \/\/ Important: Keep top at 0px for the fixed state for smooth transition later\n\n    \/\/ Cache the initial transform if any, or set it up for horizontal movement\n    \/\/ Since we want horizontal reveal, we'll control 'right' directly.\n    \/\/ If you had vertical centering, 'transform: translateY(-50%)' would go here, but we're sticking to top.\n\n    window.addEventListener('scroll', function () {\n        const scrollTop = window.pageYOffset || document.documentElement.scrollTop;\n        isScrollingDown = scrollTop > lastScrollTop;\n        lastScrollTop = scrollTop <= 0 ? 0 : scrollTop;\n\n        \/\/ --- Phase 1: Reveal and Hide (fixed position) ---\n        if (scrollTop >= activationScrollPoint && scrollTop < fullRevealScrollPoint) {\n            \/\/ Calculate progress for revealing\n            const progress = (scrollTop - activationScrollPoint) \/ (fullRevealScrollPoint - activationScrollPoint);\n            \/\/ Ensure progress is between 0 and 1\n            const clampedProgress = Math.min(1, Math.max(0, progress));\n\n            \/\/ Smoothly slide in from right (-100% to 0%) and fade in (0 to 1)\n            scrollContainer.style.opacity = clampedProgress.toString();\n            \/\/ Calculate right position: from -100% to 0% as progress goes from 0 to 1\n            \/\/ A more direct way: when progress is 0, right is -100%. When progress is 1, right is 0%.\n            \/\/ (1 - clampedProgress) means it goes from 1 to 0. So multiply by -100% to get 0 to -100%\n            scrollContainer.style.right = `${(1 - clampedProgress) * -100}%`;\n            scrollContainer.style.position = 'fixed';\n            scrollContainer.style.top = '0px'; \/\/ Maintain top position during fixed reveal\n\n        }\n        \/\/ --- Phase 2: Fully Visible and Sticky\/Absolute ---\n        else if (scrollTop >= fullRevealScrollPoint) {\n            scrollContainer.style.opacity = '1';\n            scrollContainer.style.right = '0px'; \/\/ Ensure it's fully visible\n\n            \/\/ Check if we should stick to the top or scroll with content\n            if (scrollTop >= stickToTopScrollPoint) {\n                \/\/ Once beyond stickToTopScrollPoint, change to absolute\n                \/\/ and set its top to the current scroll position so it moves with the page\n                scrollContainer.style.position = 'absolute';\n                scrollContainer.style.top = `${stickToTopScrollPoint}px`; \/\/ Stick to this specific scroll position\n            } else {\n                \/\/ Between fullRevealScrollPoint and stickToTopScrollPoint, it's fixed at the top\n                scrollContainer.style.position = 'fixed';\n                scrollContainer.style.top = '0px';\n            }\n        }\n        \/\/ --- Phase 3: Hidden (above activation point) ---\n        else {\n            scrollContainer.style.opacity = '0';\n            scrollContainer.style.right = '-100%'; \/\/ Fully hidden\n            scrollContainer.style.position = 'fixed';\n            scrollContainer.style.top = '0px'; \/\/ Reset for next reveal\n        }\n    });\n});\n<\/script>\n\n<style>\n#horizontal-scroll {\n    position: fixed; \/* Initial state, JS will change it *\/\n    right: -100%;    \/* Initial state, JS will change it *\/\n    top: 0;          \/* Consistent top position *\/\n    width: 100%;     \/* Example: or a specific pixel width *\/\n    box-sizing: border-box;\n    z-index: 9999;\n    opacity: 0;\n    \/* IMPORTANT: Remove CSS transitions for properties controlled by JS *\/\n    transition: none; \/* Disables all transitions for #horizontal-scroll *\/\n}\n<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-19ba686 elementor-widget elementor-widget-spacer\" data-id=\"19ba686\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-ae59da3 e-flex e-con-boxed e-con e-parent\" data-id=\"ae59da3\" data-element_type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-8ed75b2 e-con-full e-flex e-con e-parent\" data-id=\"8ed75b2\" data-element_type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t<div class=\"elementor-element elementor-element-cb59767 e-con-full animated-slow e-flex elementor-invisible e-con e-child\" data-id=\"cb59767\" data-element_type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;fadeIn&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-abdf6ba elementor-widget elementor-widget-heading\" data-id=\"abdf6ba\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Myasth\u00e9nie grave\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-490ba30 elementor-widget elementor-widget-text-editor\" data-id=\"490ba30\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tLa MG se manifeste typiquement par une faiblesse musculaire focalis\u00e9e qui s\u2019aggrave \u00e0 l\u2019effort et s\u2019am\u00e9liore au repos. Les sympt\u00f4mes fr\u00e9quents incluent des paupi\u00e8res tombantes, une vision floue ou double, des difficult\u00e9s \u00e0 parler ou \u00e0 avaler, une faiblesse des membres ou du cou et, dans les cas s\u00e9v\u00e8res, une d\u00e9tresse respiratoire. La progression et la s\u00e9v\u00e9rit\u00e9 varient consid\u00e9rablement d\u2019une personne \u00e0 l\u2019autre.\n\nIl n\u2019existe pas de traitement curatif, mais des options efficaces permettent de contr\u00f4ler les sympt\u00f4mes et d\u2019am\u00e9liorer la qualit\u00e9 de vie. Les immunoglobulines intraveineuses (IgIV) sont couramment utilis\u00e9es pour offrir un soulagement temporaire en modulant la r\u00e9ponse immunitaire et en r\u00e9duisant l\u2019activit\u00e9 des anticorps pathog\u00e8nes.\n\nUne option plus r\u00e9cente est l\u2019efgartigimod (Vivgart), premi\u00e8re th\u00e9rapie de sa classe approuv\u00e9e chez les patients atteints de MG g\u00e9n\u00e9ralis\u00e9e positifs aux anticorps AChR. Vivgart agit en diminuant le taux d\u2019anticorps responsables de la maladie, offrant une approche cibl\u00e9e de la prise en charge.\n\n\nR\u00e9cemment, la CNO a lanc\u00e9 un essai clinique visant \u00e0 confirmer l\u2019\u00e9quivalence th\u00e9rapeutique ou la sup\u00e9riorit\u00e9 de l\u2019efgartigimod, bloqueur du r\u00e9cepteur Fc n\u00e9onatal, par rapport aux IgIV, traitement standard utilis\u00e9 chez les personnes atteintes de myasth\u00e9nie grave g\u00e9n\u00e9ralis\u00e9e s\u00e9ropositive.\n\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-ac21547 e-con-full animated-slow e-flex elementor-invisible e-con e-child\" data-id=\"ac21547\" data-element_type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;fadeIn&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8b58e53 elementor-widget elementor-widget-heading\" data-id=\"8b58e53\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Essais cliniques actuellement en recrutement\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6bf1eeb elementor-widget elementor-widget-text-editor\" data-id=\"6bf1eeb\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div><strong>Vivgard in IVIG (\u00e9tude VIIM) <\/strong><\/div>\n<div>Population cible : myasth\u00e9nie grave g\u00e9n\u00e9ralis\u00e9e (AChR +), 18 \u00e0 80 ans<\/div>\n<div>Pour plus d\u2019information, contactez Victorine Sikati Foko \u00e0<a href=\"mailto:victorine.sikatifoko@neuro-outaouais.ca\" target=\"_blank\" rel=\"noopener noreferrer\">\u00a0victorine.sikatifoko@neuro-outaouais.ca<\/a><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b79ee9a elementor-align-left elementor-widget elementor-widget-button\" data-id=\"b79ee9a\" data-element_type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"\/myasthenia-gravis\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Participer<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Myasth\u00e9nie grave La derni\u00e8re d\u00e9cennie a profond\u00e9ment transform\u00e9 le paysage th\u00e9rapeutique de la myasth\u00e9nie grave. De nouveaux traitements aux m\u00e9canismes innovants, notamment la d\u00e9pl\u00e9tion des lymphocytes B, l\u2019inhibition du compl\u00e9ment et le blocage du r\u00e9cepteur Fc n\u00e9onatal, sont d\u00e9sormais disponibles et offrent la perspective de r\u00e9missions prolong\u00e9es. Participer Active and Recruiting CA-NEU-96 Vivgard in IVIG [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":6635,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"wf_page_folders":[11],"class_list":["post-6751","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Myasth\u00e9nie grave - Neuro-Outaouais<\/title>\n<meta name=\"description\" content=\"Prenez part aux essais Neuro Outaouais sur la myasth\u00e9nie grave. Ensemble, ouvrons la voie \u00e0 de nouvelles options th\u00e9rapeutiques.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/myasthenie-grave\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Myasth\u00e9nie grave - Neuro-Outaouais\" \/>\n<meta property=\"og:description\" content=\"Prenez part aux essais Neuro Outaouais sur la myasth\u00e9nie grave. Ensemble, ouvrons la voie \u00e0 de nouvelles options th\u00e9rapeutiques.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/myasthenie-grave\/\" \/>\n<meta property=\"og:site_name\" content=\"Neuro-Outaouais\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-04T13:20:55+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/myasthenie-grave\/\",\"url\":\"https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/myasthenie-grave\/\",\"name\":\"Myasth\u00e9nie grave - Neuro-Outaouais\",\"isPartOf\":{\"@id\":\"https:\/\/www.neuro-outaouais.com\/#website\"},\"datePublished\":\"2025-06-12T16:58:36+00:00\",\"dateModified\":\"2025-11-04T13:20:55+00:00\",\"description\":\"Prenez part aux essais Neuro Outaouais sur la myasth\u00e9nie grave. Ensemble, ouvrons la voie \u00e0 de nouvelles options th\u00e9rapeutiques.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/myasthenie-grave\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/myasthenie-grave\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/myasthenie-grave\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.neuro-outaouais.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Essais cliniques\",\"item\":\"https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Myasth\u00e9nie grave\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.neuro-outaouais.com\/#website\",\"url\":\"https:\/\/www.neuro-outaouais.com\/\",\"name\":\"My blog\",\"description\":\"We are a non-profit dedicated to expanding the breadth of medical care for people with neurological diseases.\",\"publisher\":{\"@id\":\"https:\/\/www.neuro-outaouais.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.neuro-outaouais.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.neuro-outaouais.com\/#organization\",\"name\":\"My blog\",\"url\":\"https:\/\/www.neuro-outaouais.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.neuro-outaouais.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.neuro-outaouais.com\/wp-content\/uploads\/2025\/04\/21f72584-071b-4bae-ab40-e19dc1dfa7ff.png\",\"contentUrl\":\"https:\/\/www.neuro-outaouais.com\/wp-content\/uploads\/2025\/04\/21f72584-071b-4bae-ab40-e19dc1dfa7ff.png\",\"width\":180,\"height\":89,\"caption\":\"My blog\"},\"image\":{\"@id\":\"https:\/\/www.neuro-outaouais.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Myasth\u00e9nie grave - Neuro-Outaouais","description":"Prenez part aux essais Neuro Outaouais sur la myasth\u00e9nie grave. Ensemble, ouvrons la voie \u00e0 de nouvelles options th\u00e9rapeutiques.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/myasthenie-grave\/","og_locale":"fr_CA","og_type":"article","og_title":"Myasth\u00e9nie grave - Neuro-Outaouais","og_description":"Prenez part aux essais Neuro Outaouais sur la myasth\u00e9nie grave. Ensemble, ouvrons la voie \u00e0 de nouvelles options th\u00e9rapeutiques.","og_url":"https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/myasthenie-grave\/","og_site_name":"Neuro-Outaouais","article_modified_time":"2025-11-04T13:20:55+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/myasthenie-grave\/","url":"https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/myasthenie-grave\/","name":"Myasth\u00e9nie grave - Neuro-Outaouais","isPartOf":{"@id":"https:\/\/www.neuro-outaouais.com\/#website"},"datePublished":"2025-06-12T16:58:36+00:00","dateModified":"2025-11-04T13:20:55+00:00","description":"Prenez part aux essais Neuro Outaouais sur la myasth\u00e9nie grave. Ensemble, ouvrons la voie \u00e0 de nouvelles options th\u00e9rapeutiques.","breadcrumb":{"@id":"https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/myasthenie-grave\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/myasthenie-grave\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/myasthenie-grave\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.neuro-outaouais.com\/"},{"@type":"ListItem","position":2,"name":"Essais cliniques","item":"https:\/\/www.neuro-outaouais.com\/fr\/essais-cliniques\/"},{"@type":"ListItem","position":3,"name":"Myasth\u00e9nie grave"}]},{"@type":"WebSite","@id":"https:\/\/www.neuro-outaouais.com\/#website","url":"https:\/\/www.neuro-outaouais.com\/","name":"My blog","description":"We are a non-profit dedicated to expanding the breadth of medical care for people with neurological diseases.","publisher":{"@id":"https:\/\/www.neuro-outaouais.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.neuro-outaouais.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.neuro-outaouais.com\/#organization","name":"My blog","url":"https:\/\/www.neuro-outaouais.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.neuro-outaouais.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.neuro-outaouais.com\/wp-content\/uploads\/2025\/04\/21f72584-071b-4bae-ab40-e19dc1dfa7ff.png","contentUrl":"https:\/\/www.neuro-outaouais.com\/wp-content\/uploads\/2025\/04\/21f72584-071b-4bae-ab40-e19dc1dfa7ff.png","width":180,"height":89,"caption":"My blog"},"image":{"@id":"https:\/\/www.neuro-outaouais.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/pages\/6751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/comments?post=6751"}],"version-history":[{"count":7,"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/pages\/6751\/revisions"}],"predecessor-version":[{"id":8524,"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/pages\/6751\/revisions\/8524"}],"up":[{"embeddable":true,"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/pages\/6635"}],"wp:attachment":[{"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/media?parent=6751"}],"wp:term":[{"taxonomy":"wf_page_folders","embeddable":true,"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/wf_page_folders?post=6751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}